Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioStem Technologies, Inc. Common Stock

BioStem Technologies, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.12 USD -0.01 ( 0.89%)
Last update at 2026-11-09T21:00:00Z
VOLUME
177566
Market Cap
78.07M
P/E
5.27

Momentum Score

…

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.06
Low
1.28
High
52 Week Price Range
3.09
Low
15.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioStem Technologies, Inc. is an OTCQB-listed company that appears to operate in regenerative medicine and stem cell technologies, but public disclosure about its operations and pipeline is limited. Long-term growth drivers for the sector include aging populations, rising demand for regenerative therapies, and scientific advances, and investors may find upside if the company advances programs, secures partnerships, or obtains funding.

Key risks are limited transparency, constrained financial resources and low liquidity, an early-stage pipeline with regulatory and clinical uncertainty, and dilution from future financings.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.13
Dividend Yield
-
Revenue TTM
47.48M
Revenue Per Share
2.84
Gross Profit TTM
44.44M
Debt / Equity
-
ROE
-16.45%
Net Debt
4.47M
ROCE
75.72%
Diluted EPS TTM
0.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax 30.61M -8.48M -7.11M -1.41M -2.37M
Minority interest - 0.00M 0.04M -0.03M -0.02M
Net income 31.88M -8.48M -7.07M -1.45M -2.39M
Selling general administrative 254.75M 22.63M 10.43M 4.19M 3.09M
Gross profit 288.08M 15.42M 5.99M 2.87M 1.25M
Reconciled depreciation 0.29M 0.23M 0.24M 0.28M 0.24M
Ebit - - -4.68M -1.61M -
Ebitda - - -6.40M -0.60M -1.59M
Operating income 31.20M -7.78M -4.68M -1.61M -1.84M
Interest expense 0.59M 0.70M 0.47M 0.53M 0.53M
Tax provision -1.27M 0.00M - - 0.00M
Interest income - - - - 0.00M
Net interest income -0.59M -0.70M -0.47M -0.53M -0.53M
Total revenue 301.83M 16.69M 6.88M 4.34M 2.52M
Total operating expenses 270.63M 24.46M 11.56M 5.95M 4.36M
Cost of revenue 13.75M 1.26M 0.88M 1.47M 1.27M
Total other income expense net - -0.00M -1.96M 0.72M -
Net income from continuing ops 31.88M -8.48M -7.11M -1.41M -2.37M
Net income applicable to common shares - - -7.07M -1.45M -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 140.38M 14.56M 3.47M 2.67M 2.67M
Intangible assets 0.22M 0.35M 0.36M 0.21M -
Other current assets 2.87M 0.33M 0.28M 0.04M -0.00M
Total liab 99.50M 15.54M 7.42M 8.47M 8.30M
Total stockholder equity 40.88M -0.98M -4.08M -5.96M -5.80M
Other current liab 0.71M 0.29M 0.16M 0.34M 0.19M
Common stock - - 0.01M 0.01M -
Capital stock 0.02M 0.02M 0.01M 0.01M 3.68M
Retained earnings -13.74M -45.00M -37.02M -29.95M -28.20M
Other liab - - 0.05M 0.12M -
Good will 0.24M 0.24M 0.24M 0.24M 0.47M
Other assets - - -0.00M - -
Cash 22.83M 0.24M 0.77M 0.34M 0.10M
Total current liabilities 99.17M 15.26M 6.33M 6.54M 6.80M
Net debt - 4.47M 4.30M 4.46M 5.21M
Short long term debt 3.96M 4.45M 4.04M 3.00M 3.99M
Property plant equipment - - 1.37M 1.28M -
Total current assets 133.76M 12.60M 1.49M 0.94M 0.85M
Net tangible assets - - -4.68M -6.41M -
Net receivables 104.98M 11.37M 0.04M 0.30M 0.01M
Long term debt 0.15M 0.27M 1.03M 1.80M 1.32M
Inventory 1.82M 0.66M 0.40M 0.26M 0.57M
Accounts payable 5.29M 1.03M 0.57M 0.65M 0.61M
Non current assets total 6.61M 1.96M 1.98M 1.73M 1.82M
Capital lease obligations 0.29M 0.01M 0.02M 0.03M 0.31M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.68M -0.21M -0.47M -0.01M 0.00M
Change to liabilities - - -0.08M -0.02M -
Total cashflows from investing activities - - -0.47M -0.01M -
Net borrowings -0.85M 0.80M 0.52M 0.23M -
Total cash from financing activities -0.21M 3.18M 0.57M 0.36M 0.54M
Change to operating activities - - -0.04M 0.61M -
Net income 31.88M -7.86M -7.07M -1.45M -2.39M
Change in cash 22.59M -0.53M 0.43M 0.24M -0.04M
Begin period cash flow 0.24M 0.77M 0.34M 0.10M 0.14M
End period cash flow 22.83M 0.24M 0.77M 0.34M 0.10M
Total cash from operating activities 24.48M -3.50M -1.64M -0.11M -0.58M
Issuance of capital stock - 2.38M 0.05M 0.12M -
Depreciation 0.29M 0.23M 0.24M 0.28M 0.24M
Change to inventory -1.17M -0.26M -0.14M 0.21M -0.01M
Change to account receivables -93.78M -11.33M 0.26M -0.29M 0.07M
Sale purchase of stock -0.00M 0.00M - - -
Change to netincome - - 5.19M 0.54M -
Capital expenditures 0.43M 0.21M 0.24M 0.04M 0.00M
Change in working capital -12.01M -3.08M 0.01M 0.52M 0.92M
Stock based compensation 6.66M 5.76M 4.90M 0.40M -
Other non cash items 0.46M 1.46M 0.32M 0.79M 0.38M
Free cash flow 24.05M -3.71M -2.11M -0.15M -0.58M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BSEM
BioStem Technologies, Inc. Common Stock		 -0.01
0.89%		 1.12 5.27 13.62 1.64 1.52 0.18 3.34
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

BioStem Technologies, Inc. Common Stock

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

4901 Northwest 17th Way, Fort Lauderdale, FL, United States, 33309

954 380 8342

https://biostemtechnologies.com

Name Title Year Born
Mr. Jason Matuszewski Interim Chairman, CEO, Pres & Sec. NA
Mr. Michael Fortunato CPA Chief Financial Officer NA
Mr. Andrew Vanvurst COO & Director NA
Dr. David M. Woynarowski Chief Medical Officer NA
Mr. Larry Jones Chief Revenue Officer NA
Dr. Irmgard Huber M.D. International Medical Advisor & Interim Chief Medical Officer NA
Mr. Jason Matuszewski CEO, President, Director & Secretary NA
Mr. Shawn F. McCarrey Chief Commercial Officer 1958
Mr. Jason V. Matuszewski CEO, President, Director & Secretary 1986
Mr. Michael A. Fortunato CPA Chief Financial Officer 1967

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…